1Alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts

FEBS Lett. 1998 Oct 9;436(3):329-34. doi: 10.1016/s0014-5793(98)01153-3.


1Alpha,25-dihydroxyvitamin D3 (1,25-(OH)2-D3), the active metabolite of vitamin D, can inhibit NF-kappaB activity in human MRC-5 fibroblasts, targeting DNA binding of NF-kappaB but not translocation of its subunits p50 and p65. The partial inhibition of NF-kappaB DNA binding by 1,25-(OH)2-D3 is dependent on de novo protein synthesis, suggesting that 1,25-(OH)2-D3 may regulate expression of cellular factors which contribute to reduced DNA binding of NF-kappaB. Although NF-kappaB binding is decreased by 1,25-(OH)2-D3 in MRC-5 cells, IL-8 and IL-6 mRNA levels are only moderately downregulated, demonstrating that inhibition of NF-kappaB DNA binding alone is not sufficient for optimal downregulation of these genes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Calcitriol / pharmacology*
  • Cell Line
  • Cell Nucleus / metabolism
  • DNA / metabolism*
  • Dexamethasone / pharmacology
  • Fibroblasts
  • Gene Expression Regulation / drug effects
  • Humans
  • Interleukin-1 / pharmacology
  • Interleukin-6 / genetics
  • Interleukin-8 / genetics
  • Lung
  • Macromolecular Substances
  • NF-kappa B / metabolism*
  • Promoter Regions, Genetic
  • Protein Binding
  • RNA, Messenger / metabolism
  • Transcription, Genetic / drug effects


  • Interleukin-1
  • Interleukin-6
  • Interleukin-8
  • Macromolecular Substances
  • NF-kappa B
  • RNA, Messenger
  • Dexamethasone
  • DNA
  • Calcitriol